Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
| ▸ | WEE1 | P30291 | 7/20 | 0.52 |
| ▸ | AXL | P30530 | 9/20 | 0.50 |
| ▸ | TYRO3 | Q06418 | 9/20 | 0.50 |
| ▸ | MERTK | Q12866 | 9/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | BPTF | Q12830 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31442105 | 0.94 | WEE1 (0.52) | METALKWEE1AXLTYRO3 | |
| SCHEMBL26624018 | 0.82 | MET (0.53) | METALKWEE1AXLTYRO3 | |
| SCHEMBL31442100 | 0.81 | AXL (0.53) | METALKWEE1AXLTYRO3 | |
| SCHEMBL31248082 | 0.81 | ROCK1 (0.61) | METALKWEE1TYRO3BTK | |
| SCHEMBL30642937 | 0.80 | WEE1 (0.52) | METALKWEE1AXLTYRO3 | |
| SCHEMBL26624006 | 0.80 | WEE1 (0.52) | METALKWEE1AXLTYRO3 | |
| SCHEMBL31442262 | 0.80 | INSR (0.54) | METALKWEE1AXLTYRO3 | |
| SCHEMBL31442236 | 0.80 | PDGFRA (0.52) | METALKWEE1AXLTYRO3 | |
| SCHEMBL31442083 | 0.80 | ROCK1 (0.62) | METALKWEE1AXLTYRO3 | |
| SCHEMBL31441943 | 0.79 | BTK (0.56) | AXLTYRO3MERTKBTKBPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025063645-A1 | NOVEL COMPOUND HAVING INHIBITORY ACTIVITY AGAINST HPK1 AND MLK3, AND ANTICANCER COMPOSITION CONTAINING SAME | (주)엠디바이오팜 | 2025-03-27 | — | — | WO | disclosed |